LAKE FOREST, Ill., Jan. 20, 2015 /PRNewswire/ -- Hospira, Inc.
(NYSE: HSP), the world's leading provider of injectable drugs
and infusion technologies, today announced that the company has
received 510(k) regulatory clearance from the U.S. Food and Drug
Administration (FDA) for the Plum 360™ infusion system with Hospira
MedNet™ safety software. The newest in Hospira's portfolio of
infusion devices, the Plum 360 system builds on the unique air
management and secondary delivery features of Plum A+™, while
expanding its drug library and wireless capability to enable
streamlined electronic medical record (EMR) integration.
"Hospira is excited to announce clearance of the Plum 360
infusion system in the United
States -- another important milestone in our continued path
to streamline and modernize our device portfolio," said David
J. Endicott, president, Hospira Medical Devices. "Hospira will
continue to develop and launch the most technologically advanced
infusion pumps in the industry for our customers and patients."
The Plum 360 infusion system with Hospira MedNet safety software
is designed to help improve the safety and efficiency of
intravenous (I.V.) medication administration, with benefits
including:
- infusion programming that defaults to the Hospira MedNet drug
library for advanced patient safety;
- large drug library capacity with fast keypad drug search for
ease of programming;
- improved wireless communication to expedite drug library
updates and optimize EMR connectivity with automated programming
and documentation;
- smart secondary delivery, so the pump can differentiate between
primary and secondary infusion lines and deliver each as intended;
and,
- unique air management that doesn't require disconnecting the
administration set from the patient to clear the air from the
line.
Plum 360 will be fully available to customers in the United States in the coming weeks.
The introduction of Plum 360 with Hospira MedNet is a
complementary addition to Hospira's medication management
portfolio, which also features products such as the Plum A+™
infusion system; the Sapphire™ ambulatory infusion system*; the
recently cleared SapphirePlus™ large-volume general-infusion
device*, and the market-leading LifeCare PCA™ pain management pump
with Hospira MedNet.
About Hospira
Hospira, Inc. is the world's
leading provider of injectable drugs and infusion technologies, and
a global leader in biosimilars. Through its broad, integrated
portfolio, Hospira is uniquely positioned to Advance
Wellness™ by improving patient and caregiver safety while reducing
healthcare costs. The company is headquartered in Lake Forest,
Ill. Learn more at www.hospira.com.
Private Securities Litigation Reform Act of
1995 —
A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding Hospira's goals, plans and
strategy related to Hospira's global devices. Hospira cautions that
these forward-looking statements are subject to risks and
uncertainties, including adequate and sustained progress on the
company's quality initiatives and device strategy that may cause
actual results to differ materially from those indicated in the
forward-looking statements. Economic, competitive, governmental,
regulatory, legal, technological, manufacturing supply, quality,
modernizing and streamlining activities, and other factors that may
affect Hospira's operations and may cause actual results to be
materially different from expectations include the risks,
uncertainties and factors discussed under the headings "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in Hospira's latest Annual
Report on Form 10-K and subsequent Forms 10-Q, filed with the U.S.
Securities and Exchange Commission, which are incorporated by
reference. Hospira undertakes no obligation to release publicly any
revisions to forward-looking statements as the result of subsequent
events or developments, except as required by law.
* Sapphire™ and SapphirePlus™ are trademarks of Q Core Medical
Ltd.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hospira-receives-fda-clearance-for-plum-360-infusion-system-300022844.html
SOURCE Hospira, Inc.